GUTSFractyl Health, Inc.

1. Oct 22, 2026On October 21, 2026, Fractyl Health, Inc. (the “Company”) adopted a plan to sharpen its strategic focus on its Revita ® program in connection with a strategic reprioritization.Exit or disposal costs (restructuring) · Form 8-K
2. Oct 16, 2026On October 16, 2026, the Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation.Regulation FD disclosure · Form 8-K
3. Oct 1, 2026On September 30, 2026, Fractyl Health, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Stock Split”) of its …Charter/bylaw amendment or fiscal-year change · Form 8-K
4. Sep 11, 2026As previously disclosed, on March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued …Delisting notice / listing-rule failure · Form 8-K
5. Aug 10, 2026Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
6. Jul 15, 2026On July 15, 2026, the Company reported one-year data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for weight maintenance following GLP-1 drug discontinuation.Regulation FD disclosure · Form 8-K
7. Jun 4, 2026On June 4, 2026, the Company announced positive one-year results from its open-label REVEAL-1 Cohort in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy.Regulation FD disclosure · Form 8-K
8. May 12, 2026Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates.Earnings release · press release
9. May 11, 2026Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes.Regulation FD disclosure · press release
10. Mar 24, 2026Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.